Posted on 9/21/17
September 30 'Funding Cliff' Threatens Closure of Community Health Centers Nationwide
In a matter of days, every community health center in the country faces a "funding cliff," as the federal Community Health Centers Fund is set to . . .
Posted on 9/20/17
iBio Intellectual Property Update
NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO), a leading provider of plant-based biotechnology for developing and manufacturing biological products, provided an . . .
Posted on 9/20/17
Adfinitas Health Selects Continuum as their Revenue Cycle Management Partner
Adfinitas Health, the largest private hospitalist group in the Mid-Atlantic region, has selected Continuum Health, a value-based care strategy and management company, as their revenue cycle . . .
Posted on 9/19/17
Q BioMed Announces Development Partnership with Sphaera Pharma
New York-based Q BioMed Inc., a biotechnology acceleration company, announced today a partnership with Sphaera Pharma to develop a new and proprietary analog of QBM-001 for . . .
Posted on 9/19/17
Billionaire George Soros' Fund Bought These 3 Pharma Stocks: Should You?
Billionaire George Soros is an iconic figure in the world of investing because of his unique ability to consistently beat the broader markets. As such, the . . .
Posted on 9/19/17
The Top Cancer Immunotherapies Expected to Reach $1 Billion in Sales in 2017
There is perhaps no scarier word in the English language than "cancer." More than 15.5 million Americans who were alive as of Jan. 1, 2016, have . . .
Posted on 9/19/17
3 High-Yield Healthcare Stocks
One downside to a long-lasting bull market is that the market's dividend yield declines. That's a big problem for retirees who rely on their portfolio to . . .
Posted on 9/18/17
Better Buy: Pfizer Inc. vs. Bristol-Myers Squibb
You can call them "frenemies."Pfizer (NYSE:PFE) and Bristol-Myers Squibb (NYSE:BMY) are friends when it comes to blockbuster blood thinner Eliquis. But the two big pharma companies . . .
Posted on 9/18/17
Pfizer Punches Back at Johnson & Johnson in Prostate Cancer
After winning Food and Drug Administration (FDA) approval for use in castration-resistant metastatic prostate cancer in 2012, Pfizer's (NYSE:PFE) Xtandi quickly gained ground on Johnson & . . .
Posted on 9/18/17
The Smartest Move Johnson & Johnson Has Made All Year
Healthcare conglomerate Johnson & Johnson (NYSE:JNJ) is what you might call a stalwart in the portfolios of risk-averse, income-seeking long-term investors. It's about as rock-solid as . . .
Posted on 9/18/17
10 Rock-Solid Reasons Johnson & Johnson's Near-Term Future Looks Bright
Johnson & Johnson (NYSE:JNJ) reported anemic overall sales growth in the first half of 2017. The big healthcare company even saw a decline in year-over-year earnings . . .
Posted on 9/18/17
Klick Health Named 2017 Agency of the Year by PM360
TORONTO & NEW YORK--(BUSINESS WIRE)--Klick Health won the 2017 Advertising Agency of the Year Gold Award last night at the PM360 Trailblazer Awards – an annual . . .
Posted on 9/15/17
Recent Buy: Pfizer Inc.
I will be explaining my fourth buy of the month of August. Share prices of Pfizer Inc. (PFE) have been hovering between $29.00 and $36.00 for . . .
Posted on 9/14/17
MD Anderson and Daiichi Sankyo Enter Research Collaboration
The University of TexasMD Anderson Cancer Center and Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced a multi-year collaboration focused on accelerating the development of . . .
Posted on 9/14/17
Trinitas Regional Medical Center Names its New $18.7 Million Emergency Department After Renowned Hospital Executive Gary S. Horan
To honor his five decades of healthcare leadership in both New York and New Jersey, Trinitas Regional Medical Center today named its new $18.7 million Emergency . . .
Posted on 9/14/17
Regeneron's Dupixent Takes Another Step Toward Blockbuster Status
Regeneron Pharmaceuticals (NASDAQ:REGN) unveiled phase 3 study data for its autoimmune disease drug Dupixent earlier this week that show it is effective in treating asthma. The . . .
Posted on 9/14/17
Kyowa Hakko Kirin Joins Certara’s Simcyp Consortium
PRINCETON, N.J.--(BUSINESS WIRE)--Certara®, the global leader in model-informed drug development and regulatory science, today announced that Kyowa Hakko Kirin Co., Ltd. has joined the Simcyp Consortium . . .
Posted on 9/13/17
Island Dermatology Joins Schweiger Dermatology Group
Schweiger Dermatology Group is thrilled to announce it has completed the acquisition of Island Dermatology with two locations on Long Island, New York. This is the . . .
Posted on 9/13/17
OptMed Obtains Strategic Investment and License Agreement with Synecoun
OptMed, Inc., a medical device company focused on the commercialization of BondEase®, a novel surgical adhesive, announced today that it formed a strategic relationship with Synecoun, . . .
Posted on 9/13/17
Lonnie Zeltzer, MD, Joins F4CP in Recommending Drug-Free Chiropractic Care for Pediatric Pain Management
HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--The Foundation for Chiropractic Progress (F4CP), a leading voice of the chiropractic profession and sponsor of September Drug-Free Pain Management Awareness Month, emphasizes . . .
Posted on 9/13/17
Pager and Horizon Blue Cross Blue Shield of New Jersey Collaborate to Improve Access to Care
NEW YORK & NEWARK, N.J.--(BUSINESS WIRE)--Pager and Horizon Blue Cross Blue Shield of New Jersey (Horizon BCBSNJ), the oldest and largest health insurer in New Jersey . . .
Posted on 9/12/17
Alexion Announces Restructuring to Advance Corporate Strategy
NEW HAVEN, Conn.--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced an operational plan to re-align the global organization with its refocused corporate strategy. The plan is expected . . .
Posted on 9/12/17
Merck's (MRK) Management Presents at Morgan Stanley Healthcare Conference - Transcript
Merck & Co., Inc. (NYSE:MRK)Morgan Stanley Healthcare ConferenceSeptember 12, 2017, 02:50 PM ETExecutivesKen Frazier - Chief Executive OfficerRoger Perlmutter - Executive Vice President and President, Merck . . .
Posted on 9/12/17
Allergan's Patent Loophole Could Be a Huge Gift for Pfizer
The tribe has spoken.On Friday, Allergan (NYSE:AGN) announced that the Saint Regis Mohawk Tribe now owns all patents for blockbuster dry-eye disease drug Restatis. Both parties . . .
Posted on 9/12/17
Johnson & Johnson Finally Getting A Little Help
Johnson & Johnson (NYSE:JNJ) is a stock I’ve recently come around to liking. In the past, I’ve thought the valuation to be a bit much and . . .

